CALIXAR will meet international investors at Digital RESI Europe 23-25 March 2020

CALIXAR will present its new funding round that will allow it to expand its licensing business model and develop a pipeline of targets of pharmaceutical interest.

The aim of this fundraising is for CALIXAR to become a leader in the early discovery segment of drug development based on complex therapeutic targets (membrane proteins), a market predicted to be worth €70bn by 2025.

About the Digital RESI Europe Experience 2020 :

The Redefining Early Stage Investments (RESI) conference series was created by Life Science Nation (LSN) to bring together startups with early-stage investors and strategic channel partners. The goal was to maximize the capability of these companies, from seed to series B, to find partners who are a fit for their technology and stage of development.

For more information about this event : Digital RESI Europe – 2020

Share on Facebook
Share on Twitter
Share on LinkedIn